Achieving MRD negativity in AML: how important is this and how do we get there?
Open Access
- 9 December 2022
- journal article
- research article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2022 (1) , 9-14
Abstract
Multiple studies have demonstrated that patients with acute myeloid leukemia (AML) who have measurable residual disease (MRD) detected during or after treatment have higher relapse rates and worse survival than similar patients testing negative. Updated response criteria for AML reflect the understanding that achievement of complete remission (CR) with no detectable MRD using high-sensitivity tests represents a superior response over conventional cytomorphological CR alone. Potential use cases for AML MRD testing are diverse and include patient selection for clinical trials and therapeutic assignment, early relapse detection and intervention during sequential monitoring, and drug development, including deep quantification for antileukemia efficacy and as a surrogate endpoint for overall survival in regulatory approvals. Testing for AML MRD has not, however, been harmonized, and many technical and clinical questions remain. The implications of MRD test results for specific therapeutic combinations, molecular subsets, test types, treatment time points, sample types, and patient characteristics remain incompletely defined. No perfect AML MRD test or testing strategy currently exists, and the evidence basis for clinical recommendations in this rare disease is sparse but growing. It is unproven whether conversion of an MRD test result from positive to negative by additional therapeutic intervention improves relapse risk and survival. Several national- and international-level consortia have recently been initiated to advance the generation and collection of evidence to support the use of AML MRD testing in clinical practice, drug development, and regulatory approvals.Keywords
This publication has 36 references indexed in Scilit:
- Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemiaHaematologica, 2018
- Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow TransplantationAmerican Journal of Hematology, 2018
- Molecular Minimal Residual Disease in Acute Myeloid LeukemiaNew England Journal of Medicine, 2018
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyBlood, 2018
- Measurable residual disease testing in acute myeloid leukaemiaLeukemia, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysisHaematologica, 2017
- Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemiaLeukemia, 2016
- Detection of minimal disease in acute leukemia using flow cytometry: Studies in a rat model for human acute leukemiaCytometry, 1985
- BCG treatment of residual disease in acute leukemia: Studies in a rat model for human acute myelocytic leukemia (BNML)Leukemia Research, 1983